In line with the ESTRO Vision document, the ESTRO 33 Scientific Programme will aim to cover mainly the following scientific topics.

• The integration of new clinical and preclinical evidence from biology, molecular/functional and anatomic imaging in Radiation Oncology
• The physical and biological optimisation of radiation therapy
• The use of new systemic agents together with the delivery of high precision radiation therapy in a safety aware environment
• Combined-modality treatment using radiation and either cytotoxic and/or targeted therapeutics
• The use of high-precision radiotherapy used with curative intent in patients with metastatic and locally recurrent disease
• New developments in radiation oncology that further improve the safety of high-precision radiotherapy
• New approaches to adaptive radiotherapy integrating novel developments in biology, imaging, technology, and the assessment of tumour response and patient outcome
• The potential future use of novel biological modifiers of tumour and normal tissue response
• The development of validated predictive models of treatment outcome based on complex databases comprising clinical, biologic, genetic, imaging, dosimetric and population data
• Quality programmes, including clinical audit and comprehensive safety systems in Radiation and Clinical Oncology that maintain the principles of providing the highest quality of patient care and treatment in a safety-aware environment
• Health services research in radiotherapy and oncology, including the long term analysis of changes in specialist staffing in the discipline, the level of equipment, the appropriate implementation of new technology, patient access to new treatment approaches; together with the critical analysis of these strategic developments using cost-benefit, cost- utility and other means of health economic review and health technology assessment
• Clinical trials (phase 0, I, II, and III) in radiotherapy and combined modality